How Calquence Targets Lymphoma Cells
Calquence (acalabrutinib) treats certain lymphomas by inhibiting Bruton's tyrosine kinase (BTK), a protein that B-cells need to survive and multiply. In lymphomas like mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), cancer cells rely on BTK for signals that promote uncontrolled growth via the B-cell receptor pathway. By blocking BTK, Calquence disrupts these signals, leading to cancer cell death.[1][2]
Approved by the FDA for relapsed or refractory MCL and CLL/SLL, it offers a targeted oral therapy that spares healthy cells more than traditional chemotherapy.[3]
Which Lymphomas Does Calquence Treat?
Calquence is FDA-approved for:
- Mantle cell lymphoma (MCL) after at least one prior therapy.
- Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), including cases with high-risk features like 17p deletion.
- CLL/SLL in combination with obinutuzumab for first-line treatment in patients over 65 or unfit for intensive therapy.
It is not approved for other lymphomas like diffuse large B-cell lymphoma (DLBCL) outside trials.[3][4]
How Calquence Differs from Other BTK Inhibitors Like Imbruvica
Calquence is a second-generation BTK inhibitor, more selective than Imbruvica (ibrutinib). It binds irreversibly to BTK but avoids off-target effects on other kinases like EGFR and ITK, reducing side effects such as atrial fibrillation (seen in 10-15% of Imbruvica users vs. 4-9% with Calquence) and bleeding.[2][5]
| Feature | Calquence | Imbruvica |
|---------|-----------|-----------|
| BTK Selectivity | Higher (less off-target) | Lower |
| Dosing | 100 mg twice daily | 420-560 mg once daily |
| Common Side Effects | Diarrhea, headache, infections | Higher cardiac risks, diarrhea |
Both halt B-cell signaling, but Calquence's profile supports longer use.[5]
What Happens Inside Lymphoma Cells?
BTK sits in the B-cell signaling cascade. Lymphoma cells activate it through chronic antigen stimulation, triggering NF-κB and other pathways for proliferation and survival. Calquence covalently binds BTK's active site, preventing phosphorylation and downstream activation. This starves cancer cells of survival signals within hours, inducing apoptosis. Studies show BTK occupancy >90% at therapeutic doses.[1][6]
Common Side Effects and Patient Risks
Patients report infections (49%), bleeding (22%), headache (14%), and neutropenia. Cardiac events like atrial fibrillation occur but less often than with ibrutinib. Monitoring includes ECGs and infection prophylaxis. It's metabolized by CYP3A, so avoid strong inhibitors like ketoconazole.[3][4]
Treatment Duration and Response Rates
Calquence is continuous until progression or toxicity. In CLL trials (ELEVATE-TN), 88% response rate in first-line combo therapy; median progression-free survival not reached at 48 months. For MCL, overall response rate is 81%.[3][7]
When Does Calquence's Patent Expire?
Key U.S. patents for acalabrutinib expire in 2031-2033, with pediatric exclusivity potentially extending to 2034. Generic challenges are pending; no ANDAs approved yet.[8]
[1]: FDA Label for Calquence
[2]: Nature Reviews Drug Discovery on BTK inhibitors
[3]: Calquence.com Prescribing Information
[4]: NCCN Guidelines for CLL and MCL
[5]: New England Journal of Medicine ELEVATE-TN trial
[6]: Blood Journal on BTK mechanism
[7]: ACE-CL-006 trial results
[8]: DrugPatentWatch.com - Calquence Patents